Veracyte, Inc. Investigation - VCYT

Company
Veracyte, Inc. (NASDAQ: VCYT)

Learn more about the Veracyte, Inc. Investigation

Required Field

Required Field

Required Field

  • $1 - $1,000
  • $1001 - $10,000
  • $10,001 - $25,000
  • $25,001 - $50,000
  • $50,001 - $100,000
  • $100,001 - $250,000
  • $250,001 - $500,000
  • $500,000+

There is no cost or obligation for you to submit.

The submission of this form does not create an attorney-client relationship.

Please Upload related files below

Add Transactions

Purchases

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Purchases

Sales

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Alternatively, you may upload your transactions below or e-mail them to [email protected]

Upload Your Stock Tickers

Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.

Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.

Skip

Veracyte, Inc. Investigation Details

Veracyte, Inc. shareholders lost money on November 4, 2026 when the stock abruptly plummeted over 50% after the Company reported a weaker forward growth outlook for its Decipher Prostate test and narrowed its full-year revenue guidance. For the third quarter of 2026, the Company reported revenue of $151.8 million and net income of $31.5 million. However, the Company narrowed its full-year 2026 total revenue guidance to $590-$593 million from a prior range of $590-$596 million, setting the revised upper end below cited analyst expectations of $593.894 million. In the quarterly release, the Company disclosed that "Afirma outperformed, while Decipher Prostate volume was below our expectations." The Company further slashed guidance for Decipher, projecting annual incremental volumes of 12,000 to 15,000 compared to the previous roughly 20,000 estimate. CEO Marc Stapley previously claimed "Decipher is on a very straight line ... it's highly predictable ... And I don't see any reason why that kind of trend line should change in the next couple of years."

Get Started